AI Research Project Aims to Personalise Prevention and Treatments for Heart Failure

World leading AI pioneer, Orbital Global, is proud to announce that it is a member of a new Horizon Europe research and innovation consortium, which aims to personalise prevention and treatment of cardiovascular diseases. Led by Novo Nordisk and Maastricht University, the iCARE4CVD (individualised care from early risk of cardiovascular disease to established heart failure) consortium is formed of thirty-three leading international partners from civil society, academia, and industry.

Over the next four years, these organisations will work together to better understand cardiovascular diseases and optimise future prevention and treatment. By creating one database consisting of data from more than 1 million patients and using artificial intelligence, partners will look for new strategies to shift from a one-size-fits-all approach to personalised care.

Cardiovascular (CVD) disease is very prevalent worldwide with enormous socio-economic impact. It is still the most common cause of death, despite significant advantages in therapy. Due to population ageing and unhealthy lifestyle, the number of Europeans suffering from CVD currently exceeds 85 million and is still on the rise. This underscores the critical need for better care pathways to reduce the impact of CVD.

To improve patient outcomes, iCARE4CVD aims to improve four aspects of current care: 1) early diagnosis and classification into clinically meaningful subgroups; 2) risk stratification defining urgency for intervention; 3) prediction of individual treatment response; and 4) inclusion of outcomes based on patient’s perspective.

Orbital Global will harness its pioneering digital health research capabilities and its world-leading spin-out AI technology, VirtTuri® to help automate future treatments and improve prognoses. VirtTuri is a patented, regulatory compliant AI clinical informatics platform that deploys interactive hyperrealistic avatars to significantly enhance patient understanding of critical healthcare information. Proven to elevate user engagement and recall of complex healthcare information, the VirtTuri AI platform will embed within the clinical interface, providing user friendly real-time clinical information and interaction with patients.

Peter Brady, CEO of Orbital Global, comments: "Cardiovascular diseases affect 620 million people across the world and account for around 1 in 3 deaths globally. Despite individual differences in risk factors and symptoms, there is currently a standard treatment plan for all patients. Our vision is to deploy VirtTuri within this project, to better understand patients’ individual needs and configure tailored treatments in real time for them, ultimately saving lives."

Prof Hans-Peter Brunner-La Rocca, coordinator of iCARE4CVD and cardiologist at Maastricht University and Maastricht University Medical Center+ (Maastricht UMC+) adds, "As doctors we are mostly bound to a one-size-fits-all approach while treating our patients with CVD. Our mission however, within iCARE4CVD, is to personalise diagnosis and management of CVD to improve both outcome and patient satisfaction. We will achieve this by collecting data of more than 1 million subjects in a federated database, analysing them using artificial intelligence (AI) and prospectively validating personalized treatments during the second half of iCARE4CVD."

The voices of people at risk for and those living with CVDs will be at the heart of iCARE4CVD during the entire project, by using patients’ insights, opinions and wishes. They will help to translate the findings into a more patient-centric and equitable narrative around CVD and its multiple impacts on individuals from both a social and medical perspective.

iCARE4CVD will also investigate health outcomes in people with type 1 diabetes at risk of developing CVD, explains Dr Jeanette Soderberg, Director at JDRF. "With the help of such a large European collaboration, we will investigate the impact of novel therapies typically used in type 2 diabetes on clinically important outcomes in the traditionally underappreciated but growing population of type 1 diabetes at risk. With the help of biomarkers, we will also be able to determine who’s in most need for such intervention."

iCARE4CVD has been granted €22 million in funding from the Innovative Health Initiative (IHI) - a joint undertaking of the European Commission and the European life science industry. The project officially kicked off its activities across Europe in October 2023 and will run until 31 March 2028.

Horizon Europe funds scientific research in fields ranging from terminal diseases to climate technology to food and energy security. Against the odds, Orbital Global secured one of just 192 Horizon grants (with a total value of €22 million) awarded to British science programmes in 2023 - a significant decrease in research grants prior to Brexit when, in 2019, €959 million was allocated across 1,364 grants in the UK.

For more information about VirtTuri, visit https://virtturi.com.

About Orbital Global

Orbital Global is a world-leading digital services and technology company, based in the UK. Led by CEO Peter Brady and COO Hayden Allen-Vercoe, the company was founded in 2003 and has offices based in London, Suffolk, and Somerset. A TechEast 100 and Future 50 company, Orbital Global has been referred to by industry luminaries as “world leading digital experts”. Orbital Global (www.orbitalglobalgroup.com) incorporates three divisions:

Orbital Research is the world's only supplier of the Digital Real World Evidence health research methodology. This offers a low-cost solution for generating new claims on licensed medicines or medical devices. This innovative and award-winning methodology has been referred to as a “game changer” and is estimated to create over £5 billion in value for the healthcare industry, over the next 5 years. www.orbitalglobalresearch.com

Orbital Media uses the latest technology and award-winning marketing strategies to connect brands with consumers; services include app / game development, influencer outreach, community management, digital campaigns, SEO, social monitoring, digital advertising, pharmacovigilance, and global digital strategy. It works with many of the world’s biggest global companies including GSK, Johnson & Johnson, Adidas, and BT. www.orbitalmedia.com

Orbital Innovations is leading the world in developing and licensing ground-breaking technologies, that in many instances, will have a tangible impact on improving healthcare outcomes and saving lives. Specific areas of focus include artificial intelligence, virtual reality, augmented reality, and gamification. www.orbitalinnovations.com

Most Popular Now

Researchers Invent AI Model to Design Ne…

Researchers at McMaster University and Stanford University have invented a new generative artificial intelligence (AI) model which can design billions of new antibiotic molecules that are inexpensive and easy to...

ChatGPT can Produce Medical Record Notes…

The AI model ChatGPT can write administrative medical notes up to ten times faster than doctors without compromising quality. This is according to a new study conducted by researchers at...

Alcidion and Novari Health Forge Strateg…

Alcidion Group Limited, a leading provider of FHIR-native patient flow solutions for healthcare, and Novari Health, a market leader in waitlist management and referral management technologies, have joined forces to...

Greater Manchester Reaches New Milestone…

Radiologists and radiographers at Northern Care Alliance NHS Foundation Trust have become the first in Greater Manchester to use the Sectra picture archiving and communication system (PACS) to report on...

Powerful New AI can Predict People'…

A powerful new tool in artificial intelligence is able to predict whether someone is willing to be vaccinated against COVID-19. The predictive system uses a small set of data from demographics...

Can Language Models Read the Genome? Thi…

The same class of artificial intelligence that made headlines coding software and passing the bar exam has learned to read a different kind of text - the genetic code. That code...

Advancing Drug Discovery with AI: Introd…

A transformative study published in Health Data Science, a Science Partner Journal, introduces a groundbreaking end-to-end deep learning framework, known as Knowledge-Empowered Drug Discovery (KEDD), aimed at revolutionizing the field...

Study Shows Human Medical Professionals …

When looking for medical information, people can use web search engines or large language models (LLMs) like ChatGPT-4 or Google Bard. However, these artificial intelligence (AI) tools have their limitations...

Bayer and Google Cloud to Accelerate Dev…

Bayer and Google Cloud announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will...

Wanted: Young Talents. DMEA Sparks Bring…

9 - 11 April 2024, Berlin, Germany. The digital health industry urgently needs skilled workers, which is why DMEA sparks focuses on careers, jobs and supporting young people. Against the backdrop of...

Shared Digital NHS Prescribing Record co…

Implementing a single shared digital prescribing record across the NHS in England could avoid nearly 1 million drug errors every year, stopping up to 16,000 fewer patients from being harmed...

Ask Chat GPT about Your Radiation Oncolo…

Cancer patients about to undergo radiation oncology treatment have lots of questions. Could ChatGPT be the best way to get answers? A new Northwestern Medicine study tested a specially designed ChatGPT...